Adjuvant olaparib - High risk early breast cancer with BRCA1 or BRCA2 germline mutation
Bull Cancer. 2023 Sep 14:S0007-4551(23)00340-5. doi: 10.1016/j.bulcan.2023.07.004. Online ahead of print.NO ABSTRACTPMID:37716861 | DOI:10.1016/j.bulcan.2023.07.004 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 16, 2023 Category: Cancer & Oncology Authors: Ma ëva Bonneau Audrey Bellesoeur Source Type: research
Adjuvant olaparib - High risk early breast cancer with BRCA1 or BRCA2 germline mutation
Bull Cancer. 2023 Sep 14:S0007-4551(23)00340-5. doi: 10.1016/j.bulcan.2023.07.004. Online ahead of print.NO ABSTRACTPMID:37716861 | DOI:10.1016/j.bulcan.2023.07.004 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 16, 2023 Category: Cancer & Oncology Authors: Ma ëva Bonneau Audrey Bellesoeur Source Type: research
Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy
Bull Cancer. 2023 Sep 11:S0007-4551(23)00274-6. doi: 10.1016/j.bulcan.2023.05.003. Online ahead of print.NO ABSTRACTPMID:37704495 | DOI:10.1016/j.bulcan.2023.05.003 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Tarik Rabehi Stanislas Quesada Source Type: research
Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy
Bull Cancer. 2023 Sep 11:S0007-4551(23)00274-6. doi: 10.1016/j.bulcan.2023.05.003. Online ahead of print.NO ABSTRACTPMID:37704495 | DOI:10.1016/j.bulcan.2023.05.003 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Tarik Rabehi Stanislas Quesada Source Type: research
Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy
Bull Cancer. 2023 Sep 11:S0007-4551(23)00274-6. doi: 10.1016/j.bulcan.2023.05.003. Online ahead of print.NO ABSTRACTPMID:37704495 | DOI:10.1016/j.bulcan.2023.05.003 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Tarik Rabehi Stanislas Quesada Source Type: research
